Search Results
63 Results for 'Oncology'
PAGE 3 OF 3
Technology
Provoking Anti-Tumor Immune Response with Rhamnose
One promising approach to cancer treatment is to leverage the immune system. Specifically, tumors can be ‘tagged’ with foreign antigens that attract the body’s defensive antibodies. The antibodi...
Learn More
Learn More
Laura Kiessling, Rachael Sheridan, Jonathan Hudon | P120290US02
Technology
Protecting Ovaries from Chemotherapy Damage Using Proteasome Inhibitors
Primary ovary insufficiency (POI) caused by chemotherapy treatment is experienced by many cancer survivors, including up to 40 percent of reproductive-age breast cancer survivors and eight percent of ...
Learn More
Learn More
Sana Salih, Elon Roti Roti | P130111US02
Technology
Vitamin D Analogs “1D-QM” and “1D-QMS” for Cancer, Bone Disease Therapy
The hormonally active form of vitamin D, known as calcitriol or 1,25 dihydroxyvitamin D3, has shown promise for treating diseases ranging from osteoporosis to cancer to psoriasis. However, the hormone...
Learn More
Learn More
Hector DeLuca, Lori Plum, Rafal Sicinski, Izabela Sibilska-Kaminski | P120085US02
Technology
Vitamin D Analogs “3D-QM” and “3D-QMS” for Treating Cancer and Bone Diseases
The hormonally active form of vitamin D, known as calcitriol or 1,25 dihydroxyvitamin D3, has shown promise for treating diseases ranging from osteoporosis to cancer to psoriasis. However, the hormone...
Learn More
Learn More
Hector DeLuca, Lori Plum, Rafal Sicinski, Izabela Sibilska-Kaminski | P120087US02
Technology
Vitamin D Analogs for Treating Bone Cancers and Diseases
The hormonally active form of vitamin D, known as calcitriol or 1,25 dihydroxyvitamin D3, has shown promise for treating diseases ranging from osteoporosis to cancer to psoriasis. However, the hormone...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Izabela Sibilska-Kaminski, Rafal Sicinski | P100358US03
Technology
Vitamin D Analog “DA2HE” to Treat and Prevent Polyps, Hyperplastic Intestinal Disorders
The hormonally active form of vitamin D, known as calcitriol or 1,25 dihydroxyvitamin D3, has shown promise for treating diseases ranging from osteoporosis to cancer to psoriasis. However, the hormone...
Learn More
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Agnieszka Glebocka | P120347US02
Technology
Library of Glycosylated Chlorambucil Analogs for Cancer Treatment
Many of the compounds used in drug discovery by pharmaceutical companies consist of a central core structure (aglycon) and various sugar (glycosyl) attachments. Because the sugar moieties of many of t...
Learn More
Learn More
Jon Thorson, Randal Goff | P110076US02
Technology
Novel Tautomycetin Analogs Specifically Inhibit SHP-2, May Provide New Cancer Treatment
SHP-2 is an oncogene from the protein tyrosine phosphatase (PTP) superfamily. Mutations in SHP-2 can cause multiple forms of leukemia and solid tumors, as well as the autosomal dominant disorders Noo...
Learn More
Learn More
Ben Shen, Zhong-Yin Zhang | P100290US03
Technology
Novel Tautomycetin Analogs Provide Potential Natural Products for the Treatment of Cancer or Autoimmune Disease
Tautomycetin (TTN) is a complex polyketide natural product produced by Streptomyces griseochromogens. It specifically inhibits the protein phosphatases PP1 and PP2A, which are two of the four major s...
Learn More
Learn More
Ben Shen | P100341US02
Technology
Vitamin D Analog for Cancer Prevention and Treatment
The hormonally active form of vitamin D, known as calcitriol or 1,25 dihydroxyvitamin D3, has shown promise for treating diseases ranging from osteoporosis to cancer to psoriasis. However, the hormone...
Learn More
Learn More
Hector DeLuca, Katarzyna Barycka, Katarzyna Plonska-Ocypa, Rafal Barycki, Lori Plum, Margaret Clagett-Dame, Izabela Sibilska-Kaminski, Rafal Sicinski | P100077US02
Technology
Prostate Cancer and Melanoma Screening
Almost 200,000 men in the United States develop prostate cancer each year. More than 60,000 people develop melanoma. Early diagnosis is key to survival because the best treatment and prognosis for the...
Learn More
Learn More
Douglas McNeel, Edward Dunphy, Jason Dubovsky, Luke Hoeppner | P06004US
Technology
Cytotoxic Ribonuclease Variants
Ribonucleases are enzymes that catalyze the degradation of RNA. Levels of RNase activity are controlled in vivo by a ribonuclease inhibitor (RI), which binds strongly to an RNase to completely inhibit...
Learn More
Learn More
Ronald Raines, George Phillips, R. Jeremy Johnson, Jason McCoy | P05341US
Technology
Cytotoxic Ribonuclease Variants
Ribonucleases are enzymes that catalyze the degradation of RNA. Levels of RNase activity are controlled in vivo by a ribonuclease inhibitor (RI), which binds strongly to an RNase to completely inhibit...
Learn More
Learn More
Ronald Raines, Julie Mitchell, Thomas Rutkoski | P04427US